as 08-22-2025 4:00pm EST
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | WARREN |
Market Cap: | 4.1B | IPO Year: | 2013 |
Target Price: | $67.14 | AVG Volume (30 days): | 1.5M |
Analyst Decision: | Buy | Number of Analysts: | 14 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 7.72 | EPS Growth: | N/A |
52 Week Low/High: | $30.41 - $58.38 | Next Earning Date: | 08-07-2025 |
Revenue: | $1,764,929,000 | Revenue Growth: | 96.00% |
Revenue Growth (this year): | 120.38% | Revenue Growth (next year): | -50.29% |
PTCT Breaking Stock News: Dive into PTCT Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
PR Newswire
2 months ago
Insider Monkey
2 months ago
PR Newswire
2 months ago
Zacks
3 months ago
MT Newswires
3 months ago
Yahoo Finance
3 months ago
The Guardian
3 months ago
The information presented on this page, "PTCT PTC Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.